ePT--the Electronic Newsletter of Pharmaceutical Technology, Nov 8, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ePT--the Electronic Newsletter of Pharmaceutical Technology, Nov 8, 2012
News
Watson Completes Acquisition of Actavis, Will Take Actavis Name
By Patricia Van Arnum
Watson Pharmaceuticals has completed its EUR 4.25 billion ($5.4 billion) acquisition of the Actavis Group. The combination creates the world's third largest generic-drug pharmaceutical company, with anticipated pro forma combined 2012 revenues in excess of $8 billion, according to Watson.
Boehringer Ingelheim Settles False Claims Act Allegations for $95 Million
By Amy Ritter
Boehringer Ingelheim has agreed to pay $95 million to settle allegations that it improperly promoted four of its drugs.
USP Changes Heparin Labeling Requirement
By Susan Haigney
USP revises labeling requirements for Heparin.
EC Approves Europe's First Gene Therapy
By Stephanie Sutton
The European Commission has issued final approval for Europe's first gene therapy—a treatment for a rare genetic disorder that currently has no other treatment options.
Week of November 5, 2012: Merck & Co. Resolves Vioxx Lawsuit; Takeda Agrees to Acquire Envoy Therapeutics; and More
Merck & Co. Resolves Vioxx Lawsuit; Takeda Agrees to Acquire Envoy Therapeutics; and More.
Regulatory Roundup for Week of November 5, 2012
FDA pushes back goals due to Hurricane Sandy and EMA announces changes to variation regulations.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
9%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Click here